PPD to Invest in Celtic Therapeutics

October 27, 2009
PPD, Inc. (Nasdaq: PPDI) today announced it has signed an agreement to invest $100 million in Celtic Therapeutics Holdings L.P., an investment partnership organized for the purpose of identifying, acquiring and investing in a diversified portfolio of 10 to 15 novel therapeutic product candidates.
Read the full press release

Celtic Therapeutics to invest up to $15m in the development of Spirogen's cancer drug SG2000

October 08, 2009
Spirogen Limited (Spirogen), the UK-based developer of DNA-interactive drugs, today announced that the private equity firm Celtic Therapeutics Holdings LP will invest up to $15 million in the development of Spirogen’s lead cancer drug, SG2000.
Read the full press release